Year: 2026
Type: article
Abstract: The introduction of CAR (chimeric antigen receptor) T-cell therapy into clinical practice has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM). At present, two B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are used in clinical practice, but only ciltacabtagene autoleucel is approved in Brazil. In this review, we explore the advantages and challenges of integrating CAR T-cell therapy earlier in the RRMM treatment course.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7237169362
